Stephen Shuttleworth's Biography

Stephen Shuttleworth, CSO, Karus Therapeutics

Stephen joined Karus in January 2008 as Chief Scientific Officer. He has 17 years experience in small molecule drug discovery and R&D management gained in the UK and North American biotech industry, including at Celltech-Chiroscience, Shire Pharmaceuticals, Amgen, and Piramed where he was Director of Chemistry and PI3K Programme Leader. At Piramed, Stephen was responsible for the design and preclinical development of GDC-0941, which is currently in clinical trials for the treatment of cancer, and he played a central role in establishing a major R&D collaboration with Genentech in 2005. Prior to Karus, Stephen was Head of New Projects Development at CRUK in London, responsible for CRUK's New Agents Committee and for establishing the portfolio of Phase I and II clinical programmes.
Stephen obtained his BSc and PhD in Chemistry from the University of Liverpool. He has authored more than 90 publications and patents, and is a Fellow of the Royal Society of Chemistry.